Stockhead on MSN2h
In big news week Neurizon secures key orphan status for motor neurone drug in Europe
Twas the week before Christmas and the good news was flowing for clinical stage biotech Neurizon Therapeutics (ASX:NUZ), ...
Neurizon Files IND Application to Support HEALEY ALS Platform Trial
Highlights: IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase ...
Neurizon Therapeutics Moves Forward with ALS Trial
Pharmaust Limited (AU:NUZ) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...
FOX40 News29d
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
These innovative studies reveal NUZ-001's unique mechanism of action in preventing the aggregation of TAR DNA-binding protein 43 (TDP-43), a key pathological feature of ALS, and the ability of NUZ ...
Stockhead on MSN2d
Positive interim study results for Neurizon’s motor neurone disease drug
Neurizon Therapeutics has reported a positive interim eight-month update on its ongoing 12-month open-label extension (OLE) ...
Stockhead on MSN1d
Neurizon files key IND application with US FDA for motor neurone disease drug
Neurizon has filed an Investigational New Drug application with the US FDA for lead drug candidate NUZ-001 to treat ...
Neurizon Secures EU Orphan Status for ALS Drug
Pharmaust Limited (AU:NUZ) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...
Yahoo Finance1mon
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Provides valuable insights into the mechanism of action of NUZ-001 in ALS and strengthens promising efficacy results from the Phase 1 MEND study completed earlier this year in patients with ALS ...